Healthy volunteers test drug interaction in Early-Stage trial
NCT ID NCT06917872
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial studied how the antibiotic erythromycin changes the levels of a new drug called BI 1291583 in the body. Twenty healthy adults took both drugs to see if the antibiotic affects how the new drug is processed. The goal was to gather safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 1291583 (verducatib) and erythromycin
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test